-
1
-
-
48349097445
-
Pathogenic mitochondrial DNA mutations are common in the general population
-
Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008, 83:254-260.
-
(2008)
Am J Hum Genet
, vol.83
, pp. 254-260
-
-
Elliott, H.R.1
Samuels, D.C.2
Eden, J.A.3
Relton, C.L.4
Chinnery, P.F.5
-
2
-
-
39049156470
-
Prevalence of mitochondrial DNA disease in adults
-
Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008, 63:35-39.
-
(2008)
Ann Neurol
, vol.63
, pp. 35-39
-
-
Schaefer, A.M.1
McFarland, R.2
Blakely, E.L.3
-
3
-
-
0042266280
-
Minimum birth prevalence of mitochondrial respiratory chain disorders in children
-
Skladal D, Halliday J, Thorburn DR Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003, 126:1905-1912.
-
(2003)
Brain
, vol.126
, pp. 1905-1912
-
-
Skladal, D.1
Halliday, J.2
Thorburn, D.R.3
-
4
-
-
67349120136
-
Multisystem manifestations of mitochondrial disorders
-
Di Donato S Multisystem manifestations of mitochondrial disorders. J Neurol 2009, 256:693-710.
-
(2009)
J Neurol
, vol.256
, pp. 693-710
-
-
Di Donato, S.1
-
5
-
-
33645052713
-
Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders
-
Smeitink JA, Zeviani M, Turnbull DM, Jacobs HT Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. Cell Metab 2006, 3:9-13.
-
(2006)
Cell Metab
, vol.3
, pp. 9-13
-
-
Smeitink, J.A.1
Zeviani, M.2
Turnbull, D.M.3
Jacobs, H.T.4
-
6
-
-
70450206923
-
EFNS guidelines on the molecular diagnosis of mitochondrial disorders
-
Finsterer J, Harbo HF, Baets J, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009, 16:1255-1264.
-
(2009)
Eur J Neurol
, vol.16
, pp. 1255-1264
-
-
Finsterer, J.1
Harbo, H.F.2
Baets, J.3
-
7
-
-
79955701172
-
Biomarkers for mitochondrial respiratory chain disorders
-
Suomalainen A Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011, 34:277-282.
-
(2011)
J Inherit Metab Dis
, vol.34
, pp. 277-282
-
-
Suomalainen, A.1
-
8
-
-
76549086505
-
A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells
-
Shaham O, Slate NG, Goldberger O, et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci USA 2010, 107:1571-1575.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 1571-1575
-
-
Shaham, O.1
Slate, N.G.2
Goldberger, O.3
-
9
-
-
70249133648
-
Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis
-
Medja F, Allouche S, Frachon P, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. Mitochondrion 2009, 9:331-339.
-
(2009)
Mitochondrion
, vol.9
, pp. 331-339
-
-
Medja, F.1
Allouche, S.2
Frachon, P.3
-
11
-
-
34249686631
-
Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21
-
Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
-
(2007)
Cell Metab
, vol.5
, pp. 415-425
-
-
Inagaki, T.1
Dutchak, P.2
Zhao, G.3
-
12
-
-
34249711964
-
Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states
-
Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
-
(2007)
Cell Metab
, vol.5
, pp. 426-437
-
-
Badman, M.K.1
Pissios, P.2
Kennedy, A.R.3
Koukos, G.4
Flier, J.S.5
Maratos-Flier, E.6
-
13
-
-
77957743736
-
Mitochondrial myopathy induces a starvation-like response
-
Tyynismaa H, Carroll CJ, Raimundo N, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 2010, 19:3948-3958.
-
(2010)
Hum Mol Genet
, vol.19
, pp. 3948-3958
-
-
Tyynismaa, H.1
Carroll, C.J.2
Raimundo, N.3
-
14
-
-
77957359658
-
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
-
Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
-
(2010)
J Hepatol
, vol.53
, pp. 934-940
-
-
Li, H.1
Fang, Q.2
Gao, F.3
-
15
-
-
63849189712
-
Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
-
Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009, 71:369-375.
-
(2009)
Clin Endocrinol (Oxf)
, vol.71
, pp. 369-375
-
-
Mraz, M.1
Bartlova, M.2
Lacinova, Z.3
-
16
-
-
0019559193
-
Selection and interpretation of diagnostic tests and procedures. Principles and applications
-
Griner PF, Mayewski RJ, Mushlin AI, Greenland P Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981, 94:557-592.
-
(1981)
Ann Intern Med
, vol.94
, pp. 557-592
-
-
Griner, P.F.1
Mayewski, R.J.2
Mushlin, A.I.3
Greenland, P.4
-
17
-
-
48349146527
-
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
-
Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
-
(2008)
Diabetes
, vol.57
, pp. 1246-1253
-
-
Zhang, X.1
Yeung, D.C.2
Karpisek, M.3
-
18
-
-
66749106885
-
Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects
-
Li H, Bao Y, Xy A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 2151-2156
-
-
Li, H.1
Bao, Y.2
Xy, A.3
-
19
-
-
77956276954
-
Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels
-
Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010, 163:469-477.
-
(2010)
Eur J Endocrinol
, vol.163
, pp. 469-477
-
-
Cuevas-Ramos, D.1
Almeda-Valdes, P.2
Gomez-Perez, F.J.3
-
20
-
-
77956519052
-
Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
-
Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010, 40:887-892.
-
(2010)
Eur J Clin Invest
, vol.40
, pp. 887-892
-
-
Yilmaz, Y.1
Eren, F.2
Yonal, O.3
-
21
-
-
78650850911
-
Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profiles
-
Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profiles. PLoS One 2010, 5:e15534.
-
(2010)
PLoS One
, vol.5
-
-
Lin, Z.1
Wu, Z.2
Yin, X.3
-
22
-
-
77957574072
-
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders
-
Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 2010, 33:555-561.
-
(2010)
J Inherit Metab Dis
, vol.33
, pp. 555-561
-
-
Spiekerkoetter, U.1
Bastin, J.2
Gillingham, M.3
Morris, A.4
Wijburg, F.5
Wilcken, B.6
-
23
-
-
33746878763
-
Mitochondrial complex I: structure, function and pathology
-
Janssen RJ, Nijtmans LG, van den Heuvel LP, Smeitink JA Mitochondrial complex I: structure, function and pathology. J Inherit Metab Dis 2006, 29:499-515.
-
(2006)
J Inherit Metab Dis
, vol.29
, pp. 499-515
-
-
Janssen, R.J.1
Nijtmans, L.G.2
van den Heuvel, L.P.3
Smeitink, J.A.4
-
24
-
-
54849438574
-
FGF21 is an Akt-regulated myokine
-
Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K FGF21 is an Akt-regulated myokine. FEBS Lett 2008, 582:3805-3810.
-
(2008)
FEBS Lett
, vol.582
, pp. 3805-3810
-
-
Izumiya, Y.1
Bina, H.A.2
Ouchi, N.3
Akasaki, Y.4
Kharitonenkov, A.5
Walsh, K.6
-
25
-
-
47949111205
-
Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states
-
Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol Pharmacol 2008, 74:403-412.
-
(2008)
Mol Pharmacol
, vol.74
, pp. 403-412
-
-
Muise, E.S.1
Azzolina, B.2
Kuo, D.W.3
-
26
-
-
48349127924
-
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man
-
Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008, 8:169-174.
-
(2008)
Cell Metab
, vol.8
, pp. 169-174
-
-
Galman, C.1
Lundasen, T.2
Kharitonenkov, A.3
-
27
-
-
51649118899
-
Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa
-
Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008, 93:3627-3632.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 3627-3632
-
-
Dostalova, I.1
Kavalkova, P.2
Haluzikova, D.3
-
28
-
-
77955474305
-
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease
-
Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
-
(2010)
Gastroenterology
, vol.139
, pp. 456-463
-
-
Dushay, J.1
Chui, P.C.2
Gopalakrishnan, G.S.3
-
29
-
-
78349310229
-
Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients
-
Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010, 24:2629-2637.
-
(2010)
AIDS
, vol.24
, pp. 2629-2637
-
-
Domingo, P.1
Gallego-Escuredo, J.M.2
Domingo, J.C.3
-
30
-
-
79951713560
-
Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins
-
Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011, 96:E351-E355.
-
(2011)
J Clin Endocrinol Metab
, vol.96
-
-
Tyynismaa, H.1
Raivio, T.2
Hakkarainen, A.3
-
31
-
-
23944508509
-
Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin
-
Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005, 77:430-441.
-
(2005)
Am J Hum Genet
, vol.77
, pp. 430-441
-
-
Hakonen, A.H.1
Heiskanen, S.2
Juvonen, V.3
-
32
-
-
74049124412
-
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
-
Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009, 187:875-888.
-
(2009)
J Cell Biol
, vol.187
, pp. 875-888
-
-
Ju, J.S.1
Fuentealba, R.A.2
Miller, S.E.3
-
33
-
-
1842483843
-
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
-
Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-381.
-
(2004)
Nat Genet
, vol.36
, pp. 377-381
-
-
Watts, G.D.1
Wymer, J.2
Kovach, M.J.3
|